Keele, UK, Riyadh, KSA, Stockholm, SE, and Seoul, KR; 26th February 2018 - Prokarium, the UK-based synthetic biology company that has developed Vaxonella, an oral, Read more Prokarium secures $10 million investment from Saudi, Swedish and Korean investors for clinical development of revolutionary thermostable vaccines